Sensorised “Smart” Scaffold to Monitor Cell Processes based on Impedance Characteristics

Yudan Whulanza1, a), Sotya Astutiningsih1, 2, b), and Basari1, 3, c)

1Research Center for Biomedical Engineering, Faculty of Engineering, Universitas Indonesia, Kampus UI Depok, West Java, 1625, Indonesia

2Department of Metallurgy and Material Engineering, Faculty of Engineering, Universitas Indonesia, Kampus UI Depok, West Java, 1625, Indonesia

3Department of Electrical Engineering, Faculty of Engineering, Universitas Indonesia, Kampus UI Depok, West Java, 1625, Indonesia

a)Corresponding author: yudan@eng.ui.ac.idb)sotya.astutiningsih@ui.ac.id, c)basyarie@eng.ui.ac.id

**Abstract.** Currently, one interest in tissue engineering is realizing scaffolds which not only to direct the cell process but also to monitor them. This idea can be realised by transforming a conventional scaffold into a “smart scaffold” that acts as a sensor for cell activities. Adhesive and proliferative cells modify electrical properties of adhesion substrate. Therefore it is possible to monitor their activity by monitoring the impedance of scaffold. Furthermore, impedance techniques have been used to monitor bacterial growth and cell motility of fibroblast cells. For this scope microelectrodes were used, in order to have a stable and non-invasive interface. To investigate the feasibility of designing sensorised and biocompatible scaffolds, we have realised a polymer membrane with embedded carbon nanotubes (CNT), which present electro-conductive properties. In this work we present the cell effect of composite membrane and how it is possible to monitor cell adhesion from its change.

*Keywords*: carbon nanotubes, cell processes, impedance techniques, polymer membrane, scaffolds

# Introduction

Vascular cognitive impairment (VCI) is a cognitive disorder associated with cerebrovascular disorders. VCI is a broad concept that includes all mild cognitive disorders (MCI) to Vascular Dementia (VaD) [1]. Cognitive impairment is also a major challenge in the health sector worldwide. According to the World Health Organization (WHO) this is due to the increase in the number of people suffering from cognitive impairment by 10 million each year. VCI became a big and serious problem faced by developed countries and starting to emerge in developing countries [2]. In Indonesia, the number of people with dementia in 2013 reached 1 million people and is expected to double by 2030.

Vascular cognitive impairment (VCI) is a cognitive disorder associated with cerebrovascular disorders. VCI is a broad concept that includes all mild cognitive disorders (MCI) to Vascular Dementia (VaD) [3,4]. Cognitive impairment is also a major challenge in the health sector worldwide. According to the World Health Organization (WHO) this is due to the increase in the number of people suffering from cognitive impairment by 10 million each year. VCI became a big and serious problem faced by developed countries and starting to emerge in developing countries [5,6,7]. In Indonesia, the number of people with dementia in 2013 reached 1 million people and is expected to double by 2030.

# materials and methods

Upon to the ethical approval no 0621/UN2.F1/ETIK/2018, the donors for PRFM were screened for HIV, hepatitis B and C, and cytomegalovirus infections. All donors with no reactions were informed and the concerns were signed afterwards.

Ut wisi enim ad minim veniam, quis nostrud exerci eliton ullamcorper suscipit lobortis nisl ut aliquip ex en commodo consequat. Duis te feugifacilisi per suscipit lobortis nisl ut aliquip ex en commodo consequat. Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diem nonummy nibh euismod tincidunt ut lacreet dolore magna aliguam erat volutpat.

## HSCs Isolation

Umbilical cord blood was collected from Dr. Cipto Mangunkusumo General Hospital after the participants were given informed consent. The protocols used in this study was approved by the Ethics Committee of the Faculty of Medicine, Universitas Indonesia – Dr. Cipto Mangunkusumo General Hospital. HSCs isolation was conducted as described in our previous work [9]. Briefly, HSCs were purified from umbilical cord blood by a magnetic-sorting method. Cell viability was counted by a dye exclusion method using trypan blue.

## Hydrogel Formation

### Alginate Microcapsules

Sodium alginate (Sigma-Aldrich, USA) was dissolved using phosphate-buffered saline without Ca2+ and Mg2+ (PBS w/o Ca/Mg) (Sigma-Aldrich) until a final concentration of 50 mg/ml. Alginate solution was mixed with cell suspension (5 × 106 cells/ml) in ratio 4:1. The mixture (10 μl) was dropped into 0.2 M CaCl2 solution under agitation at 230 rpm. The alginate microcapsules were subsequently washed with PBS w/o Ca/Mg.

Ut wisi enim ad minim veniam, quis nostrud exerci eliton ullamcorper suscipit lobortis nisl ut aliquip ex en commodo consequat. Duis te feugifacilisi per suscipit lobortis nisl ut aliquip ex en commodo consequat. Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diem nonummy nibh euismod tincidunt ut lacreet dolore magna aliguam erat volutpat.

## Preparation of scaffold

Platelet rich plasma was isolated using RegenKit®-BCT (Regenlab) followed the manufacturer instruction. Briefly, 8 ml of peripheral blood was collected into the tube, centrifuged at 1500 g for 10 min, then the resultant of plasma supernatant and platelet sediment were inverted mixed for 10 times. Then, 7 ml of the mixture was harvested, placed in a sterile 100 ml pot (Falcon) and added with sterile CaCl2 25 mM and centrifuged for 3500 rpm 10 min. The PRFM was then collected.

Ut wisi enim ad minim veniam, quis nostrud exerci eliton ullamcorper suscipit lobortis nisl ut aliquip ex en commodo consequat. Duis te feugifacilisi per suscipit lobortis nisl ut aliquip ex en commodo consequat. Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diem nonummy nibh euismod tincidunt ut lacreet dolore magna aliguam erat volutpat.

### Preparation of scaffold

Platelet rich plasma was isolated using RegenKit®-BCT (Regenlab) followed the manufacturer instruction. Briefly, 8 ml of peripheral blood was collected into the tube, centrifuged at 1500 g for 10 min, then the resultant of plasma supernatant and platelet sediment were inverted mixed for 10 times. Then, 7 ml of the mixture was harvested, placed in a sterile 100 ml pot (Falcon) and added with sterile CaCl2 25 mM and centrifuged for 3500 rpm 10 min. The PRFM was then collected.

Ut wisi enim ad minim veniam, quis nostrud exerci eliton ullamcorper suscipit lobortis nisl ut aliquip ex en commodo consequat. Duis te feugifacilisi per suscipit lobortis nisl ut aliquip ex en commodo consequat. Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diem nonummy nibh euismod tincidunt ut lacreet dolore magna aliguam erat volutpat.

# results and discussions

If you need to arrange several figures, a good tip is to place them in a table, which gives you additional control of the layout. Leave a line space between your figure and any text above it, like this one:

|  |  |
| --- | --- |
|  |  |
| (a) | (b) |

**Figure 1.** To format a figure caption, use the Microsoft Word template style: *Figure Caption*. The text “**FIGURE 1,**” which   
labels the caption, should be bold and in upper case. If figures have more than one part, each part should be labeled (a), (b), etc. Using a table, as in the above example, helps you control the layout

Cite all figures in the text consecutively. The word “Figure” **should** **be** spelled out if it is the first word of the sentence and abbreviated as “Fig.” elsewhere in the text. Place the figures as close as possible to their first mention in the text at the top or bottom of the page with the figure caption positioned below, all centered. Figures must be inserted in the text and may not follow the Reference section. Set figure captions in **9-point size**, Times Roman font. Type the word “**FIGURE 1**.” in bold uppercase, followed by a period.

Due to the wide range and complexity of tables, we simply offer an example for guidance. Please follow the style for table (and figure) captions.

|  |  |  |
| --- | --- | --- |
| **TABLE 1.** To format a table caption, the Microsoft Word template style: *Table Caption*. The text  “**TABLE 1,**” which labels the caption, should be bold and all letters capitalized. Center this text above the Table. Tables should have top and bottom rules, and a rule separating the column heads from the rest of the table only. | | |
| **Column Header Goes Here** | **Column Header Goes Here** | **Column Header Goes Here** |
| Row Name Here | x | x |
| Row Name Here | x | x |
| Row Name Here | x | x |
| Row Name Here | x | x |
| Row Name Here | x | x |

Ut wisi enim ad minim veniam, quis nostrud exerci eliton ullamcorper suscipit lobortis nisl ut aliquip ex en commodo consequat. Duis te feugifacilisi per suscipit lobortis nisl ut aliquip ex en commodo consequat. Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diem nonummy nibh euismod tincidunt ut lacreet dolore magna aliguam erat volutpat.

# conclussion

Well prepared papers enable rapid publication and reduce unnecessary work for your proceedings editor(s). The following points summarize the key issues you need to comply with when preparing your paper for Proceedings.

* **Check your article PDF file! It is not uncommon for errors to appear in PDFs generated from Microsoft Word – corrupted math, figures reflowing, etc. It is absolutely essential to very carefully check your article PDF file before sending it to the proceedings editor(s).**
* **Do not add page numbers or headers/footers**. Our article templates **deliberately** do not include these, so please do not add them.
* **Do not alter the margins of our templates**. They are carefully **designed** for AIP’s production process: Altering them can cause significant delays.
* **Prepare and format references with care**. Please prepare and **format** your references in accordance with the examples supplied with the author templates and documentation.
* **Embed all fonts into your article PDF**. The **importance** of font embedding is discussed in the section*F*ont Embedding(above). PDFs supplied without embedded fonts are often completely unusable for printing or publication purposes. In such cases, we have to return those PDFs to the proceeding’s editors for font embedding. Failure to embed fonts can cause unnecessary inconvenience to your proceedings editor(s) and publication delays for other authors. Failure to provide a replacement paper in a timely fashion may result in an article being removed from the proceedings.
* **Use clear, legible graphics and diagrams**. Readers of your paper will be grateful. If they cannot read it, they are unlikely to cite it.
* **Do not use copyrighted material without permission**. **Papers** using copyrighted material without appropriate permission and acknowledgment will be excluded from the proceedings.
* **No 1-page papers please**. 1-page, abstract-only contributions **are** not acceptable and will be excluded from the proceedings.
* **Avoid large PDF files (10 MB maximum, ideally)**. For **the** benefit of your readers, we recommend keeping your article PDF file below 10 MB. This is a recommendation, not a requirement.

# acknowledgement

Ut wisi enim ad minim veniam, quis nostrud exerci eliton ullamcorper suscipit lobortis nisl ut aliquip ex en commodo consequat. Duis te feugifacilisi per suscipit lobortis nisl ut aliquip ex en commodo consequat. Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diem nonummy nibh euismod tincidunt ut lacreet dolore magna aliguam erat volutpat.

# References

1. M. P. Brown and K. Austin, *The New Physique* (Publisher Name, Publisher City, 2005), pp. 25–30.
2. M. P. Brown and K. Austin, Appl. Phys. Letters **85**, 2503–2504 (2004).
3. R. T. Wang, “Title of Chapter,” in *Classic Physiques*, edited by R. B. Hamil (Publisher Name, Publisher City, 1999), pp. 212–213.
4. C. D. Smith and E. F. Jones, “Load-cycling in cubic press,” in *Shock Compression of Condensed Matter-2001*, Conference Proceedings 620, edited by M. D. Furnish *et al*. (American Institute of Physics, Melville, NY, 2002), pp. 651–654.
5. B. R. Jackson and T. Pitman, U.S. Patent No. 6,345,224 (8 July 2004)
6. D. L. Davids, “Recovery effects in binary aluminum alloys,” Ph.D. thesis, Harvard University, 1998.
7. R. C. Mikkelson (private communication).